Evoke Pharma Inc

Drug Manufacturers-Specialty & Generic

Prices are adjusted according to historical splits.

Evoke Pharma Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$6.72 million
Book Value:
Revenue TTM:
$2.51 million
Operating Margin TTM:
Gross Profit TTM:
$2.14 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Evoke Pharma Inc had its IPO on 2013-09-25 under the ticker symbol EVOK.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Evoke Pharma Inc has a staff strength of 4 employees.

Stock update

Shares of Evoke Pharma Inc opened at $1.93 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $1.82 - $1.98, and closed at $1.89.

This is a -5.98% slip from the previous day's closing price.

A total volume of 24,452 shares were traded at the close of the day’s session.

In the last one week, shares of Evoke Pharma Inc have slipped by -28.14%.

Evoke Pharma Inc's Key Ratios

Evoke Pharma Inc has a market cap of $6.72 million, indicating a price to book ratio of 1.0332 and a price to sales ratio of 3.0482.

In the last 12-months Evoke Pharma Inc’s revenue was $2.51 million with a gross profit of $2.14 million and an EBITDA of $0. The EBITDA ratio measures Evoke Pharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evoke Pharma Inc’s operating margin was -310.37% while its return on assets stood at -43.4% with a return of equity of -215.3%.

In Q4, Evoke Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 120.9%.

Evoke Pharma Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.1. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evoke Pharma Inc’s profitability.

Evoke Pharma Inc stock is trading at a EV to sales ratio of 0.0648 and a EV to EBITDA ratio of 0.1949. Its price to sales ratio in the trailing 12-months stood at 3.0482.

Evoke Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$11.85 million
Total Liabilities
$1.65 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Evoke Pharma Inc ended 2023 with $11.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.85 million while shareholder equity stood at $4.08 million.

Evoke Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $1.65 million in other current liabilities, 334.00 in common stock, $-115647143.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.84 million and cash and short-term investments were $9.84 million. The company’s total short-term debt was $129,074 while long-term debt stood at $0.

Evoke Pharma Inc’s total current assets stands at $11.72 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $624832.00 compared to accounts payable of $934312.00 and inventory worth $289378.00.

In 2023, Evoke Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Evoke Pharma Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Evoke Pharma Inc stock is currently trading at $1.89 per share. It touched a 52-week high of $10.536 and a 52-week low of $10.536. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $3.35 and 200-day moving average was $2.64 The short ratio stood at 2.39 indicating a short percent outstanding of 0%.

Around 246.4% of the company’s stock are held by insiders while 182% are held by institutions.

Frequently Asked Questions About Evoke Pharma Inc

The stock symbol (also called stock or share ticker) of Evoke Pharma Inc is EVOK

The IPO of Evoke Pharma Inc took place on 2013-09-25

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
SLM Corp (SLM)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.


420 Stevens Avenue, Solana Beach, CA, United States, 92075